-5%
Piperacillin: A broad-spectrum, semi-synthetic penicillin with bactericidal action via inhibition of cell wall and septum synthesis.
Tazobactam: A β-lactamase inhibitor that neutralizes many plasmid- and chromosomally-mediated enzymes responsible for penicillin resistance.
Together, the combination widens the antimicrobial spectrum to cover numerous β-lactamase–producing bacteria normally resistant to piperacillin alone.
Piperacillin + Tazobactam Injection | Tazobac 2.25 IV Infusion
This combination product contains Piperacillin, a penicillin-class antibacterial, and Tazobactam, a β-lactamase inhibitor. It is indicated for the treatment of moderate to severe infections caused by susceptible bacteria in the following conditions:
- Intra-abdominal infections: Complicated appendicitis (with rupture/abscess) and peritonitis caused by β-lactamase–producing Escherichia coli and species from the Bacteroides fragilis group (B. fragilis, B. ovatus, B. thetaiotaomicron, B. vulgatus).
- Skin and skin structure infections: Complicated/uncomplicated cases including cellulitis, abscesses, and ischemic/diabetic foot infections caused by β-lactamase–producing Staphylococcus aureus.
- Female pelvic infections: Postpartum endometritis and pelvic inflammatory disease caused by β-lactamase–producing E. coli.
- Community-acquired pneumonia (moderate severity): Due to β-lactamase–producing Haemophilus influenzae.
- Nosocomial pneumonia (moderate to severe): Caused by β-lactamase–producing Staphylococcus aureus and susceptible strains of Acinetobacter baumannii, H. influenzae, Klebsiella pneumoniae, and Pseudomonas aeruginosa. For Pseudomonas infections, use in combination with an aminoglycoside.